Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-15

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Using Multi-tracer to early diagnosis of therapy-associated cardiotoxicity using multimodality PET/MRI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging

NCT01434043

Myocardial Ischemia Coronary Artery Disease Myocardial Infarction

COMPLETED

Clinical Values of Dose Reduction Techniques in Computed Tomography (CT) Coronary Artery Imaging With 64-row Multi-Slice Helical CT

NCT01060657

Coronary Artery Disease

UNKNOWN

Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain

NCT01067456

Chest Pain Syndrome

COMPLETED PHASE4

320-slice Coronary Computed Tomography (CT) Angiography

NCT00721851

Coronary Artery Stenosis

COMPLETED

Koning Breast CT for Breast Imaging in China

NCT01792999

Breast Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study investigators evaluated cardiac uptake by different molecular probe such as FDG, FAPI-04 using multimodality PET/MRI. Previous studies have shown that increased cardiac uptake of FDG on PET may be an indicator of myocardial injury after chemotherapy. Cardiac magnetic resonance (CMR) allows for multiparametric evaluation of cardiac morphology, ventricular function, myocardial perfusion, and viability. The combination of PET with MR (PET/MR) is therefore an alternative attractive pairing for diagnostic imaging. The aim of this study is to find noninvasive and effective method for early diagnosis of cardiotoxicity after chemotherapy or immunotherapy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Positron-Emission Tomography Magnetic Resonance Imaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

therapy group

lymphoma patients planned chemotherapy or immunotherapy scheme

No interventions assigned to this group

healthy control group

Inclusion criteria for the controls were no known diseases or syndromes, within the age range from 18 to 35 years.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* availability of a clinical pre- and post-therapy clinical evaluation encompassing electrocardiogram (ECG) ;
* normal findings at pre-therapy clinical evaluation;
* cancer planned chemotherapy or immunotherapy scheme ;
* available staging FDG-PET/CT scan (PET0);